The use of erythropoietin in the treatment of post-bone marrow transplantation anemia.
The issue of the role of erythropoietin (Epo) in the erythroid reconstitution after bone marrow transplantation (BMT) has been addressed in several recent studies. A defective Epo production in response to anemia has been shown to occur in patients undergoing allogeneic BMT unlike in most of those subjected to an autologous rescue. The factors involved in the inadequate Epo production in BMT are discussed, with particular attention to the role of the immunosuppressive drug cyclosporin-A, which has been shown to inhibit Epo production in both in vivo and in vitro models. The observation of defective Epo production eventually led to the development of clinical trials of recombinant human Epo (rhEpo) administration in BMT patients; the aims of these studies were to stimulate erythroid engraftment, hence reducing blood transfusion exposure. Although the number of patients studied up to now is relatively small, a benefit from rhEpo administration in terms of accelerated erythroid engraftment seems very likely, and it may also be associated with decreased transfusional needs in most treated patients. However, further studies are needed to better define indications, dosages and schedules of rhEpo in BMT patients.
Department of Hematology, University of Firenze, Polyclinic of Careggi, Italy.
A M
AM
Vannucchi
A
A
Bosi
A
A
Grossi
S
S
Guidi
R
R
Saccardi
P
P
Bacci
L
L
Lombardini
P
P
Rossi-Ferrini
D000740:Anemia / Q000209:etiology / Q000378:metabolism / Q000628:therapy*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D004921:Erythropoietin / Q000096:biosynthesis / Q000627:therapeutic use*; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D004921:Erythropoietin